Flagship Ventures Dives Into Microbiome, Launches Seres Health
This article was originally published in The Pink Sheet Daily
Only a few biopharmaceutical start-ups have formed in the emerging microbiome space, but VC firm Flagship says its homegrown Seres Health, still somewhat stealthy, is developing a new category of drugs that aim to rebalance microbiome populations causing disease.
You may also be interested in...
Two of the VC's biotechs merged to create an immuno-microbiome company, while Seres is working with Emulate on better tech for microbiome research. UK specialty pharma Martindale acquired small hospital products-focused UK firm Viridian, and Bayer and X-Chem expanded their drug discovery alliance.
From pioneering stem-cell work to trade secrets a la Coca-Cola, what it means when a company – in this case, the RNA therapeutics developer Moderna – comes through Flagship Ventures’ VentureLabs group.
The latest biotech to emerge from Flagship Ventures’ incubator is Moderna, which plans to focus on rare diseases in-house while out-licensing its technology for larger indications.